|
Oxford BioDynamics PLC on Tuesday said it is fully committed to creating sustainable shareholder value for all shareholders as it posted a narrowed annual loss amid higher revenue and lower operating costs. The Oxford, England-based biotechnology company that develops medical tests said pretax loss narrowed 4.5% to £11.4 million in the financial year ended September 30, from £12.0 million a year ago. Revenue jumped 72% to £1.1 million from £636,000. The company highlighted that clinical test revenue multiplied to £1.1 million from about £400,000. Cost of sales increased 65% to £573,000 from £347,000. Staff costs decreased 9.5% to £5.0 million from £5.5 million. Total operating expenses came down 15% to £11.6 million from £13.7 million. Executive Chair Iain Ross said: ‘Since joining OBD in January this year, I have been impressed with the extraordinary depth and breadth of the technology and capabilities within the business. This has been an exciting period of renewal, and it is encouraging to see revenue-generating and cost-saving initiatives starting to deliver. Monthly orders for our EpiSwitch PSE test have more than doubled over the past year, highlighting the growing clinical adoption and commercial traction of our technology. ‘The successful £7 million fundraise post year end, which was supported by both new and existing shareholders, reflects confidence in the business and provides a strong foundation for the next phase of our turnaround. I want to thank our shareholders, partners, and employees for their continued support and dedication to the business. Whilst we are mindful of the challenges that lie ahead, the team are focused and fully committed to creating sustainable value for all shareholders.’ Oxford BioDynamics shares fell 4.0% to 0.24 pence each on Tuesday afternoon in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
